Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

pembrolizumab 7cemiplimab 6Nivolumab 5avelumab 3encorafenib 2binimetinib 2Radiotherapy 2Ipilimumab 2Immune Checkpoint Inhibitors 2Blood Specimen Collection 2toripalimab 1tislelizumab 1lifileucel 1lenvatinib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1Vemurafenib 1Surveys and Questionnaires 1Sirolimus 1Radiosurgery 1Prednisone 1Paclitaxel 1Oxaliplatin 1Observation 1Mohs Surgery 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Skin Neoplasms × cobimetinib × Clear all
NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
26 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡